The US Dollar Index fell 0.6% to 93.3 on December 15–22, 2017. The US dollar and crude oil are usually inversely related. The weak dollar supported oil (UCO) (DBO) prices last week. Higher oil prices benefit energy producers and funds like the Vanguard Energy ETF (VDE).
The dollar is near a two-week low. It impacts the PowerShares DB US Dollar Bullish ETF (UUP), which tracks the US dollar’s performance. The US dollar fell last week because it already priced in the new US tax bill. The tax bill aims to reduce US corporate tax from ~35% to ~21%.
US dollar’s lows and highs
US dollar and crude oil
Crude oil is a dollar-denominated commodity. A strong dollar makes crude oil expensive for crude oil importers. So, crude oil prices fell. Lower oil (UWT) prices have a bearish impact on energy companies (IXC) (IYE) like Laredo Petroleum (LPI), Chevron (CVX), ExxonMobil (XOM), and Baytex Energy (BTE).
In contrast, a weak dollar makes crude oil economical for oil importers. So, crude oil prices (USO) (UCO) rise.
The Fed might increase the US interest rate three times in 2018. It also estimates that US GDP will grow 2.5% in 2018. All of these factors would strengthen the US dollar. The expectation of a strong US dollar could pressure oil (USO) prices in 2018.
Next, we’ll discuss Cushing oil inventories.
Baker Hughes published its US crude oil rig report on December 22, 2017. The US crude oil rig count was flat at 747 on December 15–22, 2017.
Signet Jewelers (SIG) is expected to report weak fourth-quarter results on April 3.
The EIA is scheduled to release its oil and natural gas inventory data on March 27–28, which could be a short-term driver for oil and natural gas prices.
On March 22, J.P. Morgan (JPM) downgraded PPG Industries' (PPG) rating to "underweight" from "neutral."
The week ending March 22 was a mixed bag for the cannabis sector. The cannabis sector ETFs ended largely in the negative territory.
Hibbett Sports (HIBB) stock surged 22.3% as of 1:54 PM ET today as the company reported impressive results for fiscal 2019's fourth quarter, which ended on February 2.
Wall Street analysts expect a potential upside of 21.63% for Alexion Pharmaceuticals based on the stock's closing price on March 21.